SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Demythologizing the high costs of pharmaceutical research
10 references·7 citing·35 second hop
Demythologizing the high costs of pharmaceutical research (2011)Demythologizing the high costs of pharmac…Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases (2005)Strong Medicine: Creating Inc…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …The Rise and Fall of Modern Medicine (2000)The Rise and Fall of Modern M…The rise and fall of modern medicine (2000)The rise and fall of modern m…Rise and fall of modern medicine (1999)Rise and fall of modern medic…The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine (1996)The role of cost-effectivenes…The Role of Cost-effectiveness Analysis in Health and Medicine (1996)The Role of Cost-effectivenes…Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Recommendations of the Panel …Canadian Coordinating Office for Health Technology Assessment. (1992)Canadian Coordinating Office …Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective (2019)Is the Patent System a Barrie…Why Is There No Generic Insulin? Historical Origins of a Modern Problem (2015)Why Is There No Generic Insul…Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions? (2015)Why Are Cancer Drugs So Expen…High Cancer Drug Prices in the United States: Reasons and Proposed Solutions (2014)High Cancer Drug Prices in th…Market spiral pricing of cancer drugs (2013)Market spiral pricing of canc…Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System? (2012)Innovation and Access to Medi…The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies (2011)The Cost-Effectiveness of Dru…The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)The Price of Inequality: How Today's Divided Society Endangers Our Future (2015)Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries (2017)Trajectories of Injectable Cancer Drug Costs After Launch in the United States (2017)US Pharma's Financialized Business Model (2017)EuroQol - a new facility for the measurement of health-related quality of life (1990)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. (1992)Recommendations for Reporting Cost-effectiveness Analyses (1996)Variations in population health status: results from a United Kingdom national questionnaire survey (1998)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)The cost of biopharmaceutical R&D: is biotech different? (2007)Essential medicines for universal health coverage (2016)Cost-Effectiveness in Health and Medicine (1996)Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness (2006)The Pharmaceutical Nexus (2006)A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics (2015)The Education Effect on Population Health: A Reassessment (2011)Diagnosing the decline in pharmaceutical R&D efficiency (2012)When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis (2016)Generic and Specific Measurement of Health-Related Quality of Life in a Clinical Trial of Respiratory Rehabilitation (1999)When should decision-analytic modeling be used in the economic evaluation of health care? (2003)A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries (2004)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)HALYs and QALYs and DALYs, Oh My: Similarities and Differences in Summary Measures of Population Health (2002)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)The fall and rise of pharmacology – (Re-)defining the discipline? (2013)Guidelines for manuscript submission in the peer-reviewed pharmacological literature (2015)A History of Population Health (2020)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 1996Recommendations of the Panel on Cost-Effectiveness in Health and Medicine2,455 cited
  • 1996The Role of Cost-effectiveness Analysis in Health and Medicine1,168 cited
  • 1996The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine967 cited
  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 1999Rise and fall of modern medicine296 cited
  • 1992Canadian Coordinating Office for Health Technology Assessment.293 cited
  • 2005Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases237 cited
  • 2000The Rise and Fall of Modern Medicine189 cited
  • 2000The rise and fall of modern medicine89 cited

Cited by

  • 2015Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?115 cited
  • 2014High Cancer Drug Prices in the United States: Reasons and Proposed Solutions114 cited
  • 2012Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?112 cited
  • 2013Market spiral pricing of cancer drugs92 cited
  • 2015

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Why Is There No Generic Insulin? Historical Origins of a Modern Problem
81 cited
  • 2011The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies76 cited
  • 2019Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective13 cited